Public Disclosure of the Filing of New Drug and Therapeutic Biologics Applications With the US Food and Drug Administration

This cross-sectional study reviews New Drug Applications for new molecular entities and Biologics License Applications for new and biosimilar biological products submitted to the US Food and Drug Administration to assess how frequently applicants disclose applications in the media.

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Intern Med
Hlavní autoři: Chahal, Harinder Singh, Szeto, David, Chaudhry, Anam H., Sigelman, Daniel W., Kim, Stella, Lurie, Peter G.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2019
Témata:
Research Letter
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6547098/
https://ncbi.nlm.nih.gov/pubmed/31157824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2019.1213
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky